Skip to main content
Dryad

Enzyme inhibitory activity of marine alkaloid aaptamines for neurodegenerative diseases: An in silico study

Data files

Jun 26, 2025 version files 8.78 KB

Click names to download individual files

Abstract

The enzyme inhibitory activities of a dataset of 28 aaptamines are performed to identify potential multifunctional drugs for neurodegenerative diseases. First, the drug-like properties and pharmacokinetics (ADMET) study excluded 7 molecules, mostly for the non-permeability of the blood brain barrier. The binding activities of the remaining 21 candidates towards acetylcholinesterase (AChE), monoamine oxidase B (MAOB), and catechol-O-methyltransferase (COMT) enzymes are initially screened by molecular docking. The top binding complexes (A12@MAOB, A24@COMT, and A27@AChE) are simultaneously studied by molecular dynamics in water for 500 ns time-scale, and compared with the references such as safinamide (SAG), tolcapone (TOL) or donepezil (DON). The results show that two aaptamines A12 and A27 are well-positioned within the active pocket of the enzymes, exhibiting structural stability, with an RMSD of about 0.15-0.2 nm. MM-PBSA calculation indicates that the binding energy of the ligands to the corresponding targets is equal (A12vs. SAG) or much lower than the references (A24vs. TOL and A27vs. DON). The van der Waals interactions contribute more strongly to enzyme binding than the electrostatic energy. The study results suggest that A27 (lowest binding energy, -170.42 ± 14.24 kJ mol-1) is the most prominent Aaptamine candidate for the treatment of neurodegenerative disease.